Manipulating non-coding RNA regulation to generate breakthrough medicines

bt_bb_section_bottom_section_coverage_image
https://www.leptonpharma.com/wp-content/uploads/2020/03/blue_triangle_01.png
https://www.leptonpharma.com/wp-content/uploads/2020/04/service-01.jpg

About UsAbout Lepton

Lepton Pharmaceuticals Inc. focuses on subtle and precise silencing/suppression of coding RNA expression by small non-coding RNA molecules working via the DROSHA/DICER/RISC pathways, small interfering RNA (siRNA), and microRNA (miRNA) to develop therapies for unmet medical needs
About Us
https://www.leptonpharma.com/wp-content/uploads/2020/06/large_blue_triangle_04.png
https://www.leptonpharma.com/wp-content/uploads/2020/03/blue_triangle_01.png

Our ProductsLepton’s proprietary breakthrough general platform to manipulate siRNAs & microRNAs

Our Pipeline
bt_bb_section_top_section_coverage_image

NewsLatest News

30 May 2024
LEPTON Pharmaceuticals LTD and TAmiRNA GmbH enhance their collaboration
23 August 2023
Lepton Announced Completion of Filing for a Patent Application Extending the Usage of Its Castling Breakthrough Technologies
13 July 2023
Lepton Pharmaceuticals Completed the Extension Worldwide of its International Patent Covering the Breakthrough Castling Technology
https://www.leptonpharma.com/wp-content/uploads/2020/04/service_4.jpg
https://www.leptonpharma.com/wp-content/uploads/2021/04/logo_white_big-160x160.png

© 2023 Lepton Pharmaceuticals Inc.  All rights reserved
Design & Development by WCT

Our products

Our science

Terms of use